Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Characteristics and Survival Outcome of Patients with Isolated 11q Deletion Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 6746.

https://doi.org/10.1182/blood-2024-208444

Published: 2024

Journal Articles

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

Blood (2024) 144 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2024-207474

Published: 2024

Journal Articles

Efficacy of Luspatercept on Transfusion Burden and Cytopenias in Intermediate, High, and Very High Risk Myelodysplastic Syndromes

Daniel Leonard, David Sallman, Kelly Pugh, Christopher S. Bell, Najla H. Al Ali, Uma Borate, Rami S. Komrokji, Andrew M. Brunner

Blood (2024) 144 (Supplement 1): 6714.

https://doi.org/10.1182/blood-2024-207880

Published: 2024

Journal Articles

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

Jeremy V. DiGennaro, Dimitrios Drekolias, Najla H. Al Ali, Onyee Chan, Seongseok Yun, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, Rami S. Komrokji, David Sallman

Blood (2024) 144 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2024-208927

Published: 2024

Journal Articles

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Somedeb Ball, Najla H. Al Ali, Akriti G. Jain, Moazzam Shahzad, Junmin Whiting, Daniel Lastorino, Zhuoer Xie, Alison R. Walker, Onyee Chan, Eric Padron, Jongphil Kim, Jeffrey E Lancet, David Sallman, Sara M. Tinsley-Vance, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 532.

https://doi.org/10.1182/blood-2024-209273

Published: 2024

Journal Articles

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Blood (2024) 144 (Supplement 1): 666.

https://doi.org/10.1182/blood-2024-194405

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Blood (2024) 144 (Supplement 1): 2870.

https://doi.org/10.1182/blood-2024-210872

Published: 2024

Journal Articles

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Luca Lanino, Anthony M. Hunter, Nico Gagelmann, Marie Robin, Claudia Sala, Daniele Dall'Olio, Carmelo Gurnari, Lorenzo Dall'Olio, Yu-Hung Wang, Lisa Pleyer, Blanca Xicoy, Guillermo Montalban-Bravo, Lee-Yung Shih, Tamanna Haque, Omar Abdel-Wahab, Klaus Geissler, Alex Bataller, Alexandre Bazinet, Manja Meggendorfer, Ilaria Carola Casetti, Elisabetta Sauta, Erica Travaglino, Laura Palomo, Lurdes Zamora, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Esperanza Such, Guillermo Sanz, Anne Sophie Kubasch, Cristina Castilla-Llorente, Claude-Éric Bulabois, Laetitia Souchet, Hussein Awada, Massimo Bernardi, Patrizia Chiusolo, Antonio Curti, Luisa Giaccone, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Elisa Diral, Vladan Vucinic, Gregorio Maria Bergonzi, Maria Teresa Voso, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Elena Riva, Mattia Delleani, Angela Consagra, Francesca Ficara, Armando Santoro, Luciana Carota, Tiziana Sanavia, Cesare Rollo, Ahmad Kiwan, Jennifer VanOudenhove, Piero Fariselli, Najla H. Al Ali, David Sallman, Wolfgang Kern, Guillermo Garcia-Manero, Swapna Thota, Elizabeth A. Griffiths, Matilde Yung Follo, Carlo Finelli, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Rafael Bejar, Felicitas R. Thol, Nicolaus Kröger, Pierre Fenaux, Raphael Itzykson, Timothy Aaron Graubert, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Mrinal M. Patnaik, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2024-200104

Published: 2024

Journal Articles

High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms

Zhuoer Xie, Zena Komrokji, Michael Otterstatter, Ling Zhang, Lynn C. Moscinski, Najla H. Al Ali, David Sallman, Jeffrey E Lancet, Amy E. DeZern, Mikkael A. Sekeres, Rami S. Komrokji, Nancy Gillis, Eric Padron

Blood (2024) 144 (Supplement 1): 354.

https://doi.org/10.1182/blood-2024-203837

Published: 2024

Journal Articles

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Jaime Roman Diaz, Saurabh Dahiya, Francesca Emily Sillito, Maeve O'Reilly, Kai Rejeski, Veit L. Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick Locke, Jay Y. Spiegel, Najla H. Al Ali, Zachary Thompson, Jongphil Kim, Rami S. Komrokji, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7239.

https://doi.org/10.1182/blood-2024-201666

Published: 2024

Journal Articles

Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

Fatima Tuz Zahra, Faustine Ong, Moazzam Shahzad, Onyee Chan, Najla H. Al Ali, Jeffrey E Lancet, Alison R. Walker, David Sallman, Rami S. Komrokji, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Zhuoer Xie

Blood (2024) 144 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2024-211740

Published: 2024

Journal Articles

Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features

Luca Lanino, Saverio D'Amico, Giulia Maggioni, Najla H. Al Ali, Yu-Hung Wang, Carmelo Gurnari, Nico Gagelmann, Jan Philipp Bewersdorf, Somedeb Ball, Paola Guglielmelli, Manja Meggendorfer, Anthony M. Hunter, Anne Sophie Kubasch, Erica Travaglino, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Cristina Astrid Tentori, Alessandro Buizza, Elisabetta Sauta, Matteo Zampini, Elena Riva, Gianluca Asti, Mattia Delleani, Francesca Ficara, Armando Santoro, Claudia Sala, Daniele Dall'Olio, Lorenzo Dall'Olio, Tariq Kewan, Ilaria Carola Casetti, Hussein Awada, Blanca Xicoy, Vladan Vucinic, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Angela Consagra, David Sallman, Wolfgang Kern, Massimo Bernardi, Patrizia Chiusolo, Lorenza Maria Borin, Maria Teresa Voso, Lisa Pleyer, Laura Palomo, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Guillermo Garcia-Manero, Sanam Loghavi, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Nicolaus Kröger, Pierre Fenaux, Michaela Fontenay, Valeria Santini, Torsten Haferlach, Ulrich Germing, Eric Padron, Marie Robin, Francesco Passamonti, Eric Solary, Alessandro M. Vannucchi, Gastone Castellani, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2024-204826

Published: 2024

Journal Articles

CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?

Rami S. Komrokji, Zena Komrokji, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Andrew T. Kuykendall, Joseph E. Jabbour, Alison R. Walker, Jeffrey E Lancet, David Sallman, Eric Padron

Blood (2024) 144 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2024-205451

Published: 2024

Journal Articles

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

Daniel T Peters, Deedra Nicolet, Yazan F Madanat, Jesus D Gonzalez-Lugo, Alexander J. Ambinder, Onyee Chan, Michael Jamie Hochman, Najla H. Al Ali, Victoria Klein, Krzysztof Mrózek, Tara L. Lin, Alice Mims, Charles Foucar, Joshua F Zeidner

Blood (2024) 144 (Supplement 1): 324.

https://doi.org/10.1182/blood-2024-193667

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes

Rami S. Komrokji, Zena Komrokji, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Andrew T. Kuykendall, Joseph E. Jabbour, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman

Blood (2024) 144 (Supplement 1): 3217.

https://doi.org/10.1182/blood-2024-205861

Published: 2024

Journal Articles

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Blood (2024) 144 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2024-194488

Published: 2024

Journal Articles

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

Ziad Abuhelwa, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 4589.

https://doi.org/10.1182/blood-2024-204064

Published: 2024

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2024-210646

Published: 2024

NARROW

Characteristics and Survival Outcome of Patients with Isolated 11q Deletion Myelodysplastic Syndromes

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

Efficacy of Luspatercept on Transfusion Burden and Cytopenias in Intermediate, High, and Very High Risk Myelodysplastic Syndromes

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features

CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only